2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

4026 Teclistmamab and mezigdomide for relapsed/refractory multiple myeloma, the matrix phase 1b trial

Malin Hultcrantz, MD PhD, Ross Firestone, MD/PhD2, Carlyn Rose Tan, MD3, Alexander M. Lesokhin, MD4, Heather J. Landau, MD5, Sham Mailankody, MBBS6, Srideve Rajeeve, MD7, Hamza Hashmi, M.D.8, Hani Hassoun, MD9, Kylee Maclachlan, MD, PhD10, Maximilian Merz, MD11, Neha Korde, MD12, Urvi A. Shah, MD, MS, DipABLM13, Francesco Maura, MD14, Julia Caple15, Andriy Derkach, PhD16, Saad Z. Usmani, MD17
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Introduction

Bispecific antibodies (BsAbs) represent one of the most significant therapeutic advances in relapsed or refractory multiple myeloma (RRMM). In the MajesTEC-1 trial, teclistamab (Tec) therapy resulted in an overall response rate (ORR) of 63%. While the results are impressive, further response and durability optimization is needed to improve patient outcomes. Recent reports have shown that poor effector T cell function associates with BsAb nonresponse, while relapse is largely driven by antigen escape due to the selective pressure applied by continuous treatment until progression. Mezigdomide (Mezi), an oral investigational cereblon E3 ligase modulator, has been shown to enhance effector T cell function in myeloma patients and can enhance myeloma cell killing when combined with BsAbs in vitro. Here we present the results of the MATRIX trial (Mezigdomide And Teclistamab to Relieve Immune eXhaustion), which incorporates Mezi priming to reinvigorate effector T cell function followed by combination therapy with fixed-duration Tec treatment, aimed at minimizing infections and BCMA antigen escape at relapse.

 

Methods

This is an investigator-initiated dose-escalation phase 1b trial of Tec and Mezi for RRMM who have received two or more prior lines of therapy including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug (NCT07105059). Prior BCMA targeted therapy (CART/ADC) was allowed provided BCMA expression was confirmed on bone marrow plasma cells (immunohistochemistry). Prior BCMA targeted BsAb therapy was not allowed.

The trial had a 3+3 dose-escalation design with 2 dose levels of Mezi at 0.6 mg and 1.0 mg. There was a 14-day priming phase with Mezi, then a seven-day wash out period, followed by Tec step up at the standard 0.06 mg/kg, 0.3 mg/kg and 1.5 mg/kg dosing. Prophylactic tocilizumab was not given per protocol. After Tec step up, patients started combination treatment (C1D1) with Mezi 0.6/1.0 mg PO days 1-21 and Tec 3.0 mg/kg SC q4w for a fixed duration of 12 cycles followed by indefinite Mezi continuation. All patients received VZV and PJP prophylaxis, and primary IVIG prophylaxis.

The primary endpoint was to assess safety and determine the recommended phase 2 dosing. Here we report on the dose escalation component of the trial (N=6).

 

Results

Among the first six patients enrolled, Mezi doses were 0.6 mg (patients 1-3) and 1.0 mg (patients 4-6). Five were women, the median age was 71 years, and the median prior lines of therapy was 3.5 (range 2-8). Five patients had high risk cytogenetics per IMS/IMWG criteria. Three patients had prior BCMA CAR T exposure, one had plasma cell leukemia.

There were no dose limiting toxicities (DLTs) in the 0.6 mg Mezi dose cohort. There was one DLT (grade 4 neutropenia >7 days) in the 1.0 mg cohort. Additionally, all patients had grade 3 or 4 neutropenia at some time point during treatment, all responded to G-CSF. Five patients had dose reductions of Mezi and/or dose delays due to neutropenia.

Four patients developed cytokine release syndrome (CRS) during Tec step up, three grade 1 and one grade 2 CRS, all resolved with tocilizumab treatment. ICANs were not reported in any of the patients. Two patients had CRS following the first day of Mezi and Tec combination therapy (C1D1) grade 1 and 2, respectively, which resolved with tocilizumab treatment. Three patients had grade 1/2 infections, there were no grade 3/4 infections.

The ORR was 83% (5/6) and the median time to response was 1 month. Two patients responded already after the 14-day Mezi priming. Three patients had stringent complete response (sCR) and were minimal residual disease (MRD) negative. Two patients had a partial response (PR); one with short follow up, and the other patient was heavily pre-treated, including with BCMA CART therapy, and had plasma cell leukemia. The one patient who did not respond had high-risk cytogenetics and had prior exposure to both BCMA- and GPRC5D-directed CAR T therapy.

Conclusion

Mezi priming followed by Tec/Mezi combination therapy appears safe and highly effective with an ORR of 83% including in heavily pretreated and high-risk RRMM patients, nearly all of whom would not have met MajesTEC-1 eligibility criteria. Although this combination led to significant neutropenia, it was reversible and managed well with G-CSF. The trial continues accrual with additional patients at the Mezi 0.6 mg dose level and additional results will be reported at the ASH meeting.

Malin Hultcrantz, MD PhD: Intellisphere LLC - Honoraria; Curio Science LLC - Honoraria; OncLive - Honoraria; DAVA Oncology - Honoraria; Abbvie - Research Funding; SpringWorks Therapeutics - Research Funding; Bristol Myers Squibb - Research Funding; Johnson & Johnson - Research Funding; BeOne - Research Funding; The Binding Site - Research Funding; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)